[go: up one dir, main page]

MX2022013665A - Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares. - Google Patents

Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.

Info

Publication number
MX2022013665A
MX2022013665A MX2022013665A MX2022013665A MX2022013665A MX 2022013665 A MX2022013665 A MX 2022013665A MX 2022013665 A MX2022013665 A MX 2022013665A MX 2022013665 A MX2022013665 A MX 2022013665A MX 2022013665 A MX2022013665 A MX 2022013665A
Authority
MX
Mexico
Prior art keywords
compositions
methods
inflammation
treatment
ocular
Prior art date
Application number
MX2022013665A
Other languages
English (en)
Inventor
Kyle Battiston
Ian Charles Parrag
Wendy Alison Naimark
Matthew Alexander John Statham
Georgios Rizis
Original Assignee
Ripple Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ripple Therapeutics Corp filed Critical Ripple Therapeutics Corp
Publication of MX2022013665A publication Critical patent/MX2022013665A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen composiciones procesables que comprenden al menos una porción que es procesable en su forma libre. También se describen en la presente composiciones y métodos para el tratamiento de enfermedades o trastornos oculares que incluyen glaucoma, blefaritis, inflamación ocular, edema macular diabético, inflamación posterior, inflamación anterior, degeneración macular (por ejemplo, degeneración macular húmeda (AMD) o AMD seca), cirugía post-catarata y oclusión de la vena retinal. Las composiciones y métodos comprenden esteroides y prostaglandinas que demuestran actividad antiinflamatoria, disminución de la presión intraocular (IOP) y/u otras actividades deseables. La inyección de las composiciones en el ojo proporciona un beneficio terapéutico a los pacientes que padecen trastornos oculares.
MX2022013665A 2020-05-01 2021-04-29 Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares. MX2022013665A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019182P 2020-05-01 2020-05-01
PCT/IB2021/000332 WO2021220061A2 (en) 2020-05-01 2021-04-29 Heterodimer compositions and methods for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
MX2022013665A true MX2022013665A (es) 2022-11-30

Family

ID=78331821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013665A MX2022013665A (es) 2020-05-01 2021-04-29 Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.

Country Status (7)

Country Link
US (2) US11279729B2 (es)
EP (1) EP4146664A4 (es)
JP (1) JP2023524494A (es)
CN (1) CN115956083A (es)
CA (1) CA3176134A1 (es)
MX (1) MX2022013665A (es)
WO (1) WO2021220061A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146664A4 (en) 2020-05-01 2024-11-13 Ripple Therapeutics Corporation HETERODIMER COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
WO2023079362A1 (en) * 2021-11-03 2023-05-11 Ripple Therapeutics Corporation Processable compositions and use for the same

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7604M (es) 1968-04-22 1970-01-19
DE1768345B2 (de) 1968-05-03 1976-12-02 Hoechst Ag, 6000 Frankfurt Dimere steroid-21-alkylcarbonate und verfahren zu ihrer herstellung
JPS5829318B2 (ja) * 1974-03-11 1983-06-22 オノヤクヒンコウギヨウ カブシキガイシヤ プロスタグランジンルイジカゴウブツ ホウホウ
US4024871A (en) 1975-07-23 1977-05-24 Ethicon, Inc. Antimicrobial sutures
AU519132B2 (en) * 1978-01-31 1981-11-12 Kureha Kagaku Kogyo K.K. Prostaglandin-steroid conjugates
US4318908A (en) * 1979-12-06 1982-03-09 Kureha Kagaku Kogyo Kabushiki Kaisha Methylated prostaglandin derivatives
CA1148166A (en) 1981-03-04 1983-06-14 Ferdinando Danusso Esters of arylpropionic acids endowed with an anti- inflammatory activity, process for their preparation, and related pharmaceutical compositions
US4532316A (en) 1984-05-29 1985-07-30 W. L. Gore & Assoc., Inc. Phase separating polyurethane prepolymers and elastomers prepared by reacting a polyol having a molecular weight of 600-3500 and isocyanate and a low molecular weight chain extender in which the ratios of reactants have a limited range
PL257230A1 (en) 1985-12-31 1988-03-03 Zaklad Polimerow Pan Novel segmented polymer and method of obtaining them
IL88003A (en) 1987-10-16 1992-11-15 Dainippon Pharmaceutical Co Quinoline derivatives,their preparation and pharmaceutical compositions containing them
US4916193A (en) 1987-12-17 1990-04-10 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
FI106800B (fi) 1990-12-06 2001-04-12 Hoechst Ag Menetelmä uusien terapeuttisesti käyttökelpoisten dimeeristen sappihappojohdannaisten valmistamiseksi
US5321099A (en) 1992-01-02 1994-06-14 The Dow Chemical Company Blends of semi-crystalline polyamides and polyesteramides
US5217493A (en) 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
TW289020B (es) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
IT1270836B (it) 1993-10-27 1997-05-13 Archimica Spa Procedimento per la preparazione di rufloxacina e suoi sali
WO1995020567A1 (en) 1994-01-28 1995-08-03 University Of Kentucky Research Foundation Codrugs as a method of controlled drug delivery
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
CA2187110C (en) 1994-04-13 2002-03-19 Jean-Francois Rossignol Benzamide derivative, compositions containing said derivative and use thereof
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
DE19521642C2 (de) 1995-06-14 2000-11-09 Aesculap Ag & Co Kg Implantat, seine Verwendung in der Chirurgie und Verfahren zu seiner Herstellung
NZ313583A (en) 1995-08-03 1999-01-28 Paul J Santerre Fluoroligomer surface modifiers for polymers
CA2243649C (en) 1996-02-15 2009-08-04 J. Paul Santerre Bioresponsive pharmacologically-active polymers and articles made therefrom
KR0176334B1 (ko) 1996-08-19 1999-04-01 박원훈 내인체 감염성 삽입금속표면의 코팅방법 및 그 치료기술
US5728751A (en) 1996-11-25 1998-03-17 Meadox Medicals, Inc. Bonding bio-active materials to substrate surfaces
BR9808722A (pt) 1997-05-07 2000-07-11 Romark Lab Lc Composições farmacêuticas de tizoxanida e nitazoxanida
CN1271277A (zh) 1997-07-18 2000-10-25 因菲米德有限公司 用于生物活性物质控释的生物可降解的大分子的单体
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
US6468519B1 (en) 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
KR20010023852A (ko) 1997-09-10 2001-03-26 루트거스, 주립대학교 치료적으로 유용한 분해 산물을 갖는 폴리안하이드라이드
EP1555036B1 (en) 1998-04-27 2010-05-05 Surmodics Inc. Bioactive agent release coating
EP1105169A1 (en) 1998-08-20 2001-06-13 Cook Incorporated Coated implantable medical device
DE60034566T2 (de) 1999-07-27 2008-01-03 Adnexus Therapeutics, Inc., Waltham Peptidakzeptor ligationsverfahren
MXPA03000821A (es) 2000-07-27 2004-03-18 Univ Rutgers Poliesteres y poliamidas terapeuticos.
AU2001279064A1 (en) 2000-07-27 2002-02-13 Rutgers, The State University Therapeutic azo-compounds for drug delivery
NZ528994A (en) 2001-04-26 2006-02-24 Control Delivery Sys Inc Sustained release drug delivery system containing codrugs
CA2349989A1 (en) 2001-06-07 2002-12-07 Paul J. Santerre Bioactive surface modifiers for polymers and articles made therefrom
US9056048B2 (en) 2001-08-16 2015-06-16 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy
US20030158598A1 (en) 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
WO2003028527A2 (en) 2001-09-21 2003-04-10 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
AUPR879601A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
US20030118528A1 (en) 2001-11-19 2003-06-26 Walters Kenneth A. Topical delivery of codrugs
US20050164994A1 (en) 2001-12-10 2005-07-28 Control Deliver Systems, Inc. Treatment of genitourinary tract disorders
WO2003061626A1 (en) 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
WO2004016214A2 (en) 2002-08-14 2004-02-26 Medical College Of Georgia Research Institute, Inc. Methods and compositions for treatment of macular and retinal disease
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
EP1633403A2 (en) 2003-05-21 2006-03-15 Control Delivery Systems, Inc. Codrugs of diclofenac
CA2553816A1 (en) 2004-01-15 2005-08-04 Warner Chilcott Company, Inc. Di-steroidal prodrugs of ethinyl estradiol
WO2005099787A1 (en) 2004-04-06 2005-10-27 Surmodics, Inc. Coating compositions for bioactive agents
JP5247144B2 (ja) 2004-05-14 2013-07-24 インターフェース バイオロジクス インコーポレーティッド 高分子カップリング剤およびそれらから製造された薬学的に活性のあるポリマー
CA2571320C (en) 2004-05-14 2016-05-10 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
CA2467321A1 (en) 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
CN101099867A (zh) 2007-07-25 2008-01-09 福州大学 聚氨酯高分子前药物的新型原料配方及制备方法
CN102056600A (zh) 2008-04-07 2011-05-11 界面生物公司 用于治疗细菌感染的组合疗法
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
KR101726715B1 (ko) 2008-10-10 2017-04-13 폴리액티바 피티와이 리미티드 생분해성 폴리머-생물활성 모이어티 공액체
AU2012258480B2 (en) 2008-10-10 2014-10-23 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
WO2010040187A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Polymer-bioactive agent conjugates
US8461171B2 (en) 2010-02-09 2013-06-11 QRxPharma Ltd. Hybrid opioid compounds and compositions
WO2011120044A1 (en) 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
BR112013026467A2 (pt) 2011-04-12 2016-12-20 Commw Scient And Ind Reseaech Organisation análogos de prostaglandina conjugados com polímero
US8946254B2 (en) 2012-01-10 2015-02-03 Virginia Commonwealth University Bivalent ligands for the treatment of neurological disorders
WO2014000033A1 (en) 2012-06-26 2014-01-03 Polyactiva Pty Ltd Polymer-nsaid conjugate
WO2014138190A1 (en) 2013-03-06 2014-09-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cell-based compositions, cell-based bandage devices and systems and methods of treatment therewith
WO2014138437A1 (en) 2013-03-08 2014-09-12 Allergan, Inc. Steroid conjugates
MY181013A (en) 2013-03-08 2020-12-16 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
EP3461484B9 (en) 2013-03-15 2021-06-09 Aerie Pharmaceuticals, Inc. Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders
ES2773179T3 (es) 2013-03-15 2020-07-09 Ripple Therapeutics Corp Artículo médico recubierto para liberación de fármacos
SMT201800073T1 (it) 2014-04-28 2018-03-08 Orphomed Inc Dimero di buprenorfina e suo uso nel trattamento di disturbi gastrointestinali
MX375963B (es) * 2014-10-15 2025-03-07 Alcon Inc Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
CA2993951A1 (en) * 2015-07-28 2017-02-02 Layerbio, Inc. Sustained-release drug formulations for glaucoma
JP7150599B2 (ja) 2015-09-11 2022-10-11 ポリアクティヴァ・プロプライエタリー・リミテッド 生物活性剤を含むポリマーコンジュゲート
MA42953A (fr) 2015-09-22 2018-08-01 Graybug Vision Inc Composés et compositions pour le traitement de troubles oculaires
CN108350022B (zh) 2015-11-12 2021-12-03 内布拉斯加大学董事会 聚乙二醇缀合的糖皮质激素前体药物及其组合物和方法
CA3054328A1 (en) 2017-03-14 2018-09-20 Polyactiva Pty Ltd Drug-polymer conjugate
CN111465394A (zh) 2017-12-14 2020-07-28 灰色视觉公司 用于眼部递送的药物和组合物
EP3740494A4 (en) 2018-02-02 2021-11-03 Ripple Therapeutics Corporation GLASS FORMULATIONS WITH STEROID DIMERS AND USES THEREOF
WO2019210215A1 (en) 2018-04-26 2019-10-31 Graybug Vision, Inc. Drugs to treat ocular disorders
CN110746593A (zh) 2018-07-24 2020-02-04 东丽先端材料研究开发（中国）有限公司 一种多磺酸基聚合物及其在水处理中的应用
IN201841029923A (es) * 2018-08-09 2020-02-14 Gland Pharma Ltd
MX2021002380A (es) 2018-08-31 2021-07-15 Aerie Pharmaceuticals Inc Conjugados de isoquinolina-esteroide y usos de los mismos.
US20220089635A1 (en) 2019-02-01 2022-03-24 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
EP3996764A4 (en) 2019-07-10 2023-11-01 Ripple Therapeutics Corporation SURFACE COATINGS AND IMPLANTABLE DEVICES CONTAINING DIMERIC STEROID PRODRUGS AND USES THEREOF
JP2022541341A (ja) 2019-07-25 2022-09-22 リップル セラピューティクス コーポレーション ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用
US20220274999A1 (en) 2019-08-07 2022-09-01 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependance disorders
EP4146664A4 (en) 2020-05-01 2024-11-13 Ripple Therapeutics Corporation HETERODIMER COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES

Also Published As

Publication number Publication date
US20220106351A1 (en) 2022-04-07
US20210347809A1 (en) 2021-11-11
CA3176134A1 (en) 2021-11-04
WO2021220061A2 (en) 2021-11-04
EP4146664A4 (en) 2024-11-13
CN115956083A (zh) 2023-04-11
EP4146664A2 (en) 2023-03-15
US11279729B2 (en) 2022-03-22
WO2021220061A3 (en) 2021-12-23
JP2023524494A (ja) 2023-06-12

Similar Documents

Publication Publication Date Title
Baudouin et al. Inflammation in Glaucoma: From the back to the front of the eye, and beyond
Kerr et al. Intraocular pressure during femtosecond laser pretreatment of cataract
Anderson et al. Sensitivities of ocular tissues to acute pressure-induced ischemia
CO6351718A2 (es) Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular
MX2022013665A (es) Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
Mirshahi et al. Posterior segment complications of laser in situ keratomileusis (LASIK)
US9974645B2 (en) Method of reducing the occurrence of macular and neuroretinal degenerations by alleviating age related retinal stresses as a contributing factor in a mammalian eye
Halkiadakis et al. Laser in situ keratomileusis in patients with diabetes
Marzo et al. Malignant glaucoma after XEN45 implant
Pereira et al. Choroidal detachment after the use of topical latanoprost
Szigiato et al. Efficacy of ab-interno gelatin microstent implantation in primary and refractory glaucoma
Shah et al. Should we anticipate intraoperative floppy iris syndrome (IFIS) even with very short history of tamsulosin?
RU2530647C1 (ru) Способ предоперационной подготовки больного к антиглаукоматозной операции
Smith et al. Complete bilateral vitreous detachment after LASIK retreatment
Saleem et al. Iridocorneal endothelial syndrome
MX2023004538A (es) Compuestos y metodos para el tratamiento de trastornos oculares.
RU2735065C1 (ru) Способ хирургического лечения первичной субкомпенсированной открытоугольной глаукомы с наличием токсико-аллергической реакции на гипотензивную терапию
RU2815951C1 (ru) Способ лечения первичной открытоугольной глаукомы
Miyai et al. Interlamellar flap edema due to steroid-induced ocular hypertension after laser in situ keratomileusis
Barberá et al. Transepithelial phototherapeutic keratectomy to treat chronic laser in situ keratomileusis-flap macrostriae. A case review
RU2638767C1 (ru) Способ профилактики реактивной гипертензии после факоэмульсификации катаракты
Baptista The Use of Ripasudil Hydrochloride Hydrate in Endothelial Decompensation–A Case Series
KARAKÜÇÜK CURRENT TRENDS IN THE TREATMENT MODALITIES OF OPEN ANGLE GLAUCOMA
Fenech et al. Assessing the analgesic benefit of phacoemulsification under topical anesthesia using pre-operative nepafenac 0.1%
He et al. Safety and efficacy of combined trabeculectomy for primary angle closure glaucoma with persistent ocular hypertension